4D Molecular Therapeutics Inc (FDMT) - Total Liabilities
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has total liabilities worth $61.05 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
4D Molecular Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See 4D Molecular Therapeutics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
4D Molecular Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JuneYao Dairy Co Ltd
SHG:605388
|
China | CN¥352.63 Million |
|
ChoiceOne Financial Services Inc
NASDAQ:COFS
|
USA | $3.92 Billion |
|
Shanghai Guangdian Electric Group Co Ltd
SHG:601616
|
China | CN¥517.35 Million |
|
Shanghai Carthane Co Ltd
SHG:603037
|
China | CN¥358.33 Million |
|
Hunan Hengguang Technology Co.Ltd.
SHE:301118
|
China | CN¥1.20 Billion |
|
MiCo Ltd
KQ:059090
|
Korea | ₩1.12 Trillion |
|
Shenzhen Xinhao Photoelectricity Technology Co. Ltd
SHE:301051
|
China | CN¥2.61 Billion |
|
Top Gum Industries Ltd
TA:TPGM
|
Israel | ILA85.07 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down 4D Molecular Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FDMT company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 4D Molecular Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of 4D Molecular Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $61.05 Million | +22.64% |
| 2024-12-31 | $49.78 Million | +55.26% |
| 2023-12-31 | $32.06 Million | +5.09% |
| 2022-12-31 | $30.51 Million | -11.26% |
| 2021-12-31 | $34.38 Million | +7.63% |
| 2020-12-31 | $31.94 Million | -75.65% |
| 2019-12-31 | $131.20 Million | +5.34% |
| 2018-12-31 | $124.56 Million | +165.52% |
| 2017-12-31 | $46.91 Million | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more